Fig. 7From: Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVEProportions of patients with worsened VA (defined as a loss of ≥7 letters) or improved VA (defined as an increase of ≥7 letters) in both eyes over 2 years in the STRIVE OCT subgroup per protocol population (n = 50)Back to article page